New drug indication approval - November 2024
For the most updated information related to registered therapeutic products, please refer to the Register of Therapeutic Products.
| Product Name | IMJUDO CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML |
| Active Ingredient (Strength) | Tremelimumab(20 mg/mL) |
| Product Registrant | ASTRAZENECA SINGAPORE PTE LTD |
| Date of Approval | 15/11/2024 |
Indications:
Non-Small Cell Lung Cancer (NSCLC)
IMJUDO in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of patients with metastatic NSCLC with no sensitising epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. |
| Product Name | BRUKINSA™ CAPSULE 80MG |
| Active Ingredient (Strength) | Zanubrutinib(80mg) |
| Product Registrant | BEIGENE SINGAPORE PTE. LTD. |
| Date of Approval | 26/11/2024 |
Indications:
BRUKINSA is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. |
Healthcare professional, Industry member, Therapeutic Products
Published:
New Drug Indication Approvals